IGFBP2 and ovarian cancer: Screening of 34 human ovarian cancer cell lines revealed that high expression of Yes, Lyn, Eph2A, caveolin-1 and 2, moesin, annexin-1, and uPA, and low expression of insulin-like growth factor-binding protein 2 (IGFBP2) render the cells sensitive to Dasatinib treatment [16].